ASCO 2024: Innovent Biologics Delivers Oral Presentation of Clinical Data of a Randomized Controlled Phase 1b Study Evaluating IBI310 in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer
ASCO 2024: Innovent Biologics Delivers Oral Presentation of Clinical Data of a Randomized Controlled Phase 1b Study Evaluating IBI310 in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer
Impacting News June 13, 2024
Innovent Biologics Announcement at ASCO
Innovent Biologics , Inc. (HKEX: 01801)(OTC: IVBXF) announced that the clinical . . .
This content is for paid subscribers.
Please click
here to subscribe or
here to log in.
Impacting News
June 13, 2024
